Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
OBJECTIVE
Current grading systems of acute graft-versus-host disease (GVHD) cannot effectively identify patients with poor prognosis at the onset of acute GVHD after allogeneic hematopoietic cell transplantation.


METHODS
In a retrospective analysis, we evaluated the prognostic value of various clinical parameters at the initiation of treatment in 83 patients who developed systemic treatment-requiring acute GVHD after allogeneic hematopoietic cell transplantation.


RESULTS
Forty-three of 83 patients (52%) experienced initial treatment failure (40 required secondary treatment due to lack of response and 3 died) and 43 (52%) experienced treatment success, defined as completion of treatment (initial and, if given, secondary) within 100 days. The GVHD-specific survival rate was 65.5%, with 27 deaths due to GVHD-related complications without relapse of underlying malignancies within 1 year. HLA-mismatched transplantation, visceral initiation, and peripheral blood lymphocytopenia ( pound100/mL) were independent variables predicting higher initial treatment failure (Odd ratios (OR)=12.225, 12.036, and 7.481, respectively). The above variables and initial acute GVHD grade III-IV vs. II were independent variables predicting shorter GVHD-specific survival (OR=0.322, 0.247, 0.340, and 0.385, respectively). High-risk disease status, visceral initiation, and hypoalbuminemia ( pound2.8 g/dL) were independent variables predicting lower treatment success (OR=0.221, 0.162, and 0.270, respectively). The predictive value of visceral initiation and lymphocytopenia for GVHD-specific survival was verified in an independent cohort of 58 patients.


CONCLUSIONS
Lymphocytopenia and hypoalbuminemia may be useful baseline prognostic factors for acute GVHD after allogeneic hematopoietic cell transplantation.
Lee
Kyoo-Hyung
KH
Hematology Section, Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea. khlee2@amc.seoul.kr <khlee2@amc.seoul.kr>
Choi
Seong-Jun
SJ
Lee
Jung-Hee
JH
Lee
Jung-Shin
JS
Kim
Woo-Kun
WK
Lee
Kyu-Bo
KB
Sohn
Sang-Kyun
SK
Kim
Jong-Gwang
JG
Kim
Dong-Hwan
DH
Seol
Miee
M
Lee
Young-Shin
YS
Lee
Je-Hwan
JH
D000293:Adolescent; D000328:Adult; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012709:Serum Albumin / Q000096:biosynthesis; D014184:Transplantation, Homologous / Q000009:adverse effects*; D016896:Treatment Outcome
D012709:Serum Albumin